Loading organizations...
§ Private Profile · Camarillo, CA, USA
Develops CAR T-cell therapies for oncology, targeting blood cancers and solid tumors with logic-gate approaches to improve targeting.
ImmPACT Bio, based in West Hills, California, develops engineered chimeric antigen receptor (CAR) T-cell therapies designed to recognize and attack cancer cells in both blood cancers and solid tumors, utilizing logic-gate approaches to improve targeting. The company raised approximately $165.86 million in disclosed funding, notably an $18 million Series A in 2020 and a $111 million Series B in 2022, advancing its CAR-T programs into clinical study. Lead investors included venBio Partners, Foresite Capital, Decheng Capital, and OrbiMed, with Novartis Venture Fund also participating. Its scientific development was spearheaded by pioneers Yvonne Chen, Antoni Ribas, and Gideon Gross, and led by CEO Sumant Ramachandra. ImmPACT Bio was acquired by Lyell Immunopharma in October 2024, having been founded in 2017 by Yvonne Chen, Antoni Ribas, and Gideon Gross.
ImmPACT Bio has raised $166.0M across 3 funding rounds.
ImmPACT Bio has raised $166.0M in total across 3 funding rounds.
ImmPACT Bio has raised $166.0M across 3 funding rounds. Most recently, it raised $8.0M Grant in February 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 28, 2024 | $8M Grant | Abla Creasey | — | Announced |
| Jan 1, 2022 | $140M Series B | Foresite Capital, OrbiMed, Bukwang Pharmaceutical, MIN CUI, Novartis, RM Global Partners, Surveyor Capital | 5AM Ventures, Apollo Health Ventures, MPM Capital, RA Capital, VenBio Partners, Venrock | Announced |
| Aug 18, 2020 | $18M Series A | — | Bukwang Pharmaceutical, Hayan Health Networks, Johnson & Johnson Innovation, JVC Investment Partners, Novartis, OrbiMed, RM Global Partners, Takeda Ventures | Announced |
ImmPACT Bio has raised $166.0M in total across 3 funding rounds.
ImmPACT Bio's investors include Abla Creasey, Foresite Capital, OrbiMed, Bukwang Pharmaceutical, Min Cui, Novartis, RM Global Partners, Surveyor Capital, 5AM Ventures, Apollo Health Ventures, MPM Capital, RA Capital.
ImmPACT Bio is a clinical-stage biotechnology company developing logic-gate-based chimeric antigen receptor (CAR) T-cell therapies to treat cancer and autoimmune diseases, targeting cancerous or autoreactive cells while sparing healthy tissues.[1][2][3] Its lead product, IMPT-314, is a bispecific CD19/CD20 CAR T therapy in Phase I/II trials for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, with IMPT-514 advancing for multiple sclerosis after FDA IND clearance in 2025.[4][5] The company serves patients with exhausted treatment options in oncology and autoimmunity, addressing challenges like antigen escape, on-target/off-tumor toxicities, and immunosuppressive tumor microenvironments, and raised $165.86M before its October 2024 acquisition by Lyell Immunopharma.[1][5]
ImmPACT Bio was founded in 2017 within the FutuRx incubator in Israel, leveraging technologies from pioneering scientists including Prof. Gideon Gross (MIGAL – Galilee Research Institute), Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA.[2][3] In 2019, it established U.S. headquarters in West Hills, California (later Camarillo for R&D), with additional operations in Rehovot, Israel; by 2021, it merged with Kalthera to expand its pipeline.[1][3] Early traction came from licensing UCLA's logic-gate CAR T platforms, filing 7 patents (e.g., inhibitory CARs granted in 2023), and advancing to clinical stages amid CAR T's rise in hematological malignancies.[1][2]
ImmPACT Bio rides the CAR T expansion from blood cancers to solid tumors and autoimmune diseases like MS, where current therapies face antigen escape and toxicity hurdles.[3][4][5] Timing aligns with FDA nods (e.g., IMPT-514 IND in 2025) and manufacturing optimizations amid scalability demands, fueled by market forces like rising lymphoma/MS prevalence and investor interest in next-gen cell therapies.[2][4] Its acquisition by Lyell in October 2024 consolidates expertise, enabling Lyell to pivot fully to CAR T (dropping TIL programs) and launch pivotal IMPT-314 trials in 2025, influencing ecosystem shifts toward bispecific, logic-gated approaches for broader adoption.[1][5]
Post-acquisition, ImmPACT's therapies integrate into Lyell's pipeline, with IMPT-314 Phase I/II data expected soon and pivotal third-line lymphoma trials starting 2025, plus IMPT-514 dosing in MS trials mid-2025.[4][5] Trends like automated manufacturing and autoimmune CAR T applications will shape progress, potentially evolving its influence via Lyell's resources into transformative, one-time treatments resetting immune dysfunction in hard-to-treat diseases. This positions the logic-gate platform as a cornerstone for CAR T's next era, building on its targeted precision to expand beyond oncology.